Insider Selling: Equillium (NASDAQ:EQ) COO Sells $15,589.00 in Stock

Equillium, Inc. (NASDAQ:EQ) COO Christine Zedelmayer sold 11,900 shares of the business’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $1.31, for a total value of $15,589.00. Following the completion of the transaction, the chief operating officer owned 91,444 shares in the company, valued at $119,791.64. This trade represents a 11.51% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Christine Zedelmayer also recently made the following trade(s):

• On Friday, December 12th, Christine Zedelmayer sold 23,804 shares of Equillium stock. The stock was sold at an average price of $1.34, for a total value of $31,897.36.
• On Tuesday, November 25th, Christine Zedelmayer sold 8,098 shares of Equillium stock. The shares were sold at an average price of $0.95, for a total value of $7,693.10.

Equillium Price Performance

Equillium stock opened at $1.10 on Thursday. The business has a 50 day simple moving average of $1.15 and a 200-day simple moving average of $1.00. Equillium, Inc. has a 12 month low of $0.27 and a 12 month high of $2.35. The stock has a market capitalization of $66.98 million, a PE ratio of -1.77 and a beta of 1.92.

Equillium (NASDAQ:EQ) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.08. As a group, equities research analysts anticipate that Equillium, Inc. will post 0.14 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Virtu Financial LLC lifted its position in shares of Equillium by 133.4% during the 3rd quarter. Virtu Financial LLC now owns 23,779 shares of the company’s stock valued at $34,000 after acquiring an additional 13,591 shares during the period. Millennium Management LLC acquired a new stake in Equillium in the third quarter valued at $35,000. Persistent Asset Partners Ltd purchased a new position in shares of Equillium in the third quarter valued at $99,000. Boothbay Fund Management LLC acquired a new position in shares of Equillium during the 3rd quarter worth $174,000. Finally, Schonfeld Strategic Advisors LLC acquired a new position in shares of Equillium during the 3rd quarter worth $178,000. 27.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently issued reports on EQ. Wall Street Zen raised shares of Equillium from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Equillium in a research note on Monday. Two equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Reduce” and an average price target of $1.00.

Equillium Company Profile

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.